REVIVA PHARMACEUTICALS HOLDINGS, INC.

Tenzing Acquisition Corp. (NASDAQ: TZAC), sponsored by Tenzing Global Investors, was a blank-check company that completed its initial public offering in 2019 targeting opportunities in the healthcare and life sciences sectors. In July 2020, Tenzing announced a definitive business combination agreement with Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and metabolic disorders. The transaction has since closed, bringing Reviva Pharmaceuticals to the public markets. Visit SpacDesk and sign up for full access to deal timelines, SEC filing history, and in-depth analytics on TZAC and every other SPAC transaction in our database.

SPAC Counterparty (1)